The charts, technical indicators, and signals here are generated live from Tech Trader, a fully autonomous trading system with no human intervention.
The second chart (if available) is a combination of Tech Trader with the Grok AI (from xAI) interpreting the chart and making trading decisions, including elaborate reports at the bottom explaining any given day.
Follow trades and activity on The Tech Trader Wall and Tech Trader + Grok Wall.
Daily Chart
(Technical analysis chart by Tech Trader)
Grok's Analysis - Grok 4
| 2025-10-22 | CASH |
| 2025-10-21 | SOLD |
|
Summary: Exiting long ABBV to secure substantial gains from $210.42 entry amid recent volatility and approaching October 31 earnings, despite strong uptrend and positive momentum....
|
|
| 2025-10-20 | HOLD LONG |
|
Summary: Holding long ABBV as uptrend persists with price above EMA and SMA, recovering from support near $227 with positive MACD momentum and supportive pharma news on pipeline advancements without reversal signals....
|
|
| 2025-10-17 | HOLD LONG |
|
Summary: Holding long ABBV in confirmed uptrend with price above EMA and SMA, recent breakout recovery from support around $226, positive MACD momentum, and supportive pharma sector news on drug pipeline without imminent reversal risks. Price has bounced from a rising trendline support near $226.74, last tested recently, aligning with historical patterns where similar pullbacks in uptrends led to continuations, as seen in July-August rallies post-earnings....
|
|
| 2025-10-16 | HOLD LONG |
|
Summary: Holding long ABBV as it remains in a confirmed uptrend with price above EMA and SMA, recent pullback finding support at rising trendline around $226, positive momentum indicators, and no immediate reversal signals despite upcoming earnings risk....
|
|
| 2025-10-15 | HOLD LONG |
|
Summary: Holding long ABBV in confirmed uptrend with price above EMA and SMA, recent bounce from rising support at $225.32 after pullback from $244 high, supported by positive momentum and no imminent catalysts or reversal signals....
|
|
| 2025-10-13 | HOLD LONG |
|
Summary: Holding long ABBV as the uptrend continues with price above EMA and SMA, recovering from recent pullback without reversal signals, supported by positive momentum and no immediate catalysts, aiming for resistance near 233-234 before earnings....
|
|
| 2025-10-10 | HOLD LONG |
|
Summary: Holding long ABBV as the uptrend persists with price above EMA and SMA, recent pullback from highs offers no reversal signals, supported by positive momentum and no imminent catalysts, targeting hold towards resistance near 234 before upcoming earnings....
|
|
| 2025-10-09 | HOLD LONG |
|
Summary: Holding long ABBV as the uptrend remains strong with price above EMA and SMA, recent gap-up on positive news supports momentum, no reversal signals, and earnings not imminent....
|
|
| 2025-10-07 | HOLD LONG |
|
Summary: Holding long ABBV as the uptrend persists with price above EMA and SMA after a pullback from recent highs, supported by strong volume on the breakout and positive pharma sector momentum, with no clear reversal signals or imminent events....
|
|
| 2025-10-06 | HOLD LONG |
|
Summary: Holding long ABBV as the uptrend remains intact with price above EMA and SMA, recent pullback from highs appears as a healthy dip supported by strong volume on the prior breakout and positive pipeline momentum, with no reversal signals or imminent catalysts warranting exit after 19-bar hold from $210.42 entry....
|
|
| 2025-10-03 | HOLD LONG |
|
Summary: Holding long ABBV as the clear uptrend persists with price well above EMA and SMA, recent breakout to new highs on strong volume and positive momentum, supported by bullish fundamentals like robust pipeline updates and no imminent reversal signals....
|
|
| 2025-10-02 | HOLD LONG |
|
Summary: Holding long ABBV as the uptrend remains intact with price above EMA and SMA, strong momentum from recent highs on positive news, and no clear reversal signals despite today's pullback. Technical indicators support continuation: MACD is positive at 6.8754 with the line above signal, RSI at 70.25 indicates strength without extreme overbought levels, and Stochastic shows bullish momentum. Volume on the recent surge to 244.81 on 10/1 was high at over 12 million shares, suggesting strong buying interest, though today's pullback to 236.93 on lower volume appears as a healthy consolidation rather than a reversal....
|
|
| 2025-10-01 | HOLD LONG |
|
Summary: Holding long ABBV as the clear uptrend persists with price surging above EMA and SMA to new highs on strong volume, positive MACD momentum, and no reversal signals or imminent catalysts. Technical indicators support continuation: MACD is positive at 6.38 with the signal line at 5.01, RSI at 83.68 indicates overbought but not extreme given the momentum, and Stochastic is high but aligned with bullish trends. Bollinger Bands are expanding upward, with price near the upper band, suggesting strong buying pressure. Support from rising trendlines around $220 and historical levels at $205 provide downside protection, and there's no volume capitulation or bearish divergence to signal a top....
|
|
| 2025-09-30 | HOLD LONG |
|
Summary: Holding long ABBV as the uptrend remains intact with price well above EMA and SMA, strong bullish momentum to new highs, positive MACD, and no imminent catalysts or reversal signals. Technical indicators support continuation: MACD is positive at 4.9744 above its signal line at 4.6755, RSI at 76.86 is elevated but not extremely overbought in the context of this stock's historical rallies, and Stochastic is high at 92.69, reflecting sustained buying pressure. Volume on the upside break was solid at 4.7M shares, and there's no flagged volume capitulation to suggest exhaustion. Key supports include a rising trendline around $219.17 recently tested, with additional levels at $205.1 showing strength from prior bounces—avoiding entries near bottoms but here we're already positioned well above....
|
|
| 2025-09-29 | HOLD LONG |
|
Summary: Maintaining long ABBV position as uptrend persists with price above EMA and SMA, positive MACD, strong momentum to recent highs near 223 resistance, no reversal signals, and no imminent catalysts within 3 days....
|
|
| 2025-09-26 | HOLD LONG |
|
Summary: Maintaining long ABBV position as uptrend continues with price above EMA and SMA, positive MACD, strong momentum from recent highs, and no imminent catalysts or reversal signals....
|
|
| 2025-09-25 | HOLD LONG |
|
Summary: Maintaining long ABBV position as uptrend persists with price above EMA and SMA, positive MACD and momentum, no reversal signals, and supportive sector trends without near-term catalysts. Recent bars display higher highs and lows, supported by rising trendlines like the one from $202.77 with positive slope, last tested around late July. Volume has been steady without capitulation, and indicators like MACD at 4.52 (above signal) and RSI at 61.57 indicate sustained bullish momentum without overbought conditions....
|
|
| 2025-09-24 | HOLD LONG |
|
Summary: Maintaining long ABBV position as the uptrend remains intact with price above EMA and SMA, positive MACD, RSI not overbought, no reversal signals near recent highs, and supportive pharma sector trends without imminent catalysts....
|
|
| 2025-09-23 | HOLD LONG |
|
Summary: Maintaining long ABBV position in strong uptrend with price above EMA/SMA, positive MACD and RSI, recent highs at 225 without reversal, supported by bullish pharma sector momentum and no near-term catalysts, targeting 230 resistance....
|
|
| 2025-09-22 | HOLD LONG |
|
Summary: Maintaining long ABBV position as uptrend continues with price above EMA/SMA, bullish MACD and momentum, recent highs near 225 without reversal, targeting 230 resistance amid positive pharma news....
|
|
| 2025-09-19 | HOLD LONG |
|
Summary: Maintaining long ABBV position as uptrend persists with price above EMA/SMA, bullish MACD, recent breakout to new highs near 223, no reversal signals, and positive momentum from pharma sector strength, targeting 225-230 resistance....
|
|
| 2025-09-18 | HOLD LONG |
|
Summary: Maintaining long ABBV position in continued uptrend with price above EMA/SMA, positive MACD, recent highs near 221, no reversal signals, and supportive pharma news, targeting 225-230 resistance....
|
|
| 2025-09-17 | HOLD LONG |
|
Summary: Maintaining long ABBV position in strong uptrend with price above EMA/SMA, positive MACD, recent breakout to new highs above 215 resistance, and no reversal signals or imminent catalysts, targeting 225-230 zone....
|
|
| 2025-09-16 | HOLD LONG |
|
Summary: Maintaining long ABBV position in confirmed uptrend with price above EMA/SMA, positive MACD, no reversal signals, recent breakout above 210-215 resistance, and targeting 225-230 zone amid stable pharma sector and no imminent catalysts....
|
|
| 2025-09-15 | HOLD LONG |
|
Summary: Maintaining long ABBV position in confirmed uptrend with price above EMA/SMA, positive MACD momentum, no reversal signals, recent breakout to 220 highs, and targeting 225-230 resistance zone amid stable pharma fundamentals. Technical indicators support continuation: MACD at 4.5379 remains bullish above its signal line (4.3323), RSI at 67.2 indicates room for upside without overbought conditions, and Stochastic %K/%D (79.68/80.84) shows sustained momentum. Recent bars reflect a high-volume breakout above 212 resistance on 9/11, pushing to 220+ highs, mirroring past patterns like the July post-earnings rally from 189 to 198, where we captured gains without early exits....
|
|
| 2025-09-12 | HOLD LONG |
|
Summary: Maintaining long ABBV position amid confirmed uptrend with price above EMA/SMA, recent high-volume breakout above 212 resistance to new highs near 220, positive MACD and momentum, no reversal signals, and targeting 225-230 zone....
|
|
| 2025-09-11 | HOLD LONG |
|
Summary: Maintaining long ABBV position as the strong uptrend persists with price well above EMA/SMA, recent breakout to new highs on high volume, positive MACD momentum, and no reversal signals or imminent catalysts, targeting further upside toward 225-230 resistance....
|
|
| 2025-09-10 | HOLD LONG |
|
Summary: Maintaining long position in ABBV as the uptrend remains intact with price above EMA and SMA, recent close near but not exceeding 212.88 resistance, and no immediate catalysts or reversal signals after just one bar hold, targeting further upside toward 215. MACD is positive at 3.7905 with signal at 4.1955, though slightly diverging, but momentum indicators like RSI at 65.56 suggest room before overbought territory. Volume is moderate at 3.2M, not indicating exhaustion....
|
|
| 2025-09-09 | BUY |
|
Summary: Entering long in confirmed uptrend with price above EMA and SMA, positive MACD crossover, and bullish momentum from recent highs, supported by strong pharma fundamentals and no imminent catalysts, targeting multi-week hold towards 215 resistance. Technical indicators are supportive: RSI at 62.3 indicates room for upside without being overbought, MACD at 3.89 with signal at 4.29 showing positive momentum, and the price is within Bollinger Bands, not at the upper extreme (upper at 215.27). Support levels at 182.37 and rising trendlines around 195-198 provide a safety net, while resistance at 212.88 suggests potential for a move higher....
|
|
| 2025-09-08 | CASH |
|
Summary: Staying in cash as the uptrend persists but current price at 209.04 isn't a meaningful dip from recent highs near 213 or our 8/29 exit at 210.4, with no new catalysts justifying quick re-entry and potential resistance at 212.88 ahead....
|
|
| 2025-09-05 | CASH |
|
Summary: Staying in cash as the uptrend persists but price is near resistance at $212.88 without a clear dip for entry, and we recently exited at $210.4 with no significant new bullish catalysts to justify re-entry so soon at a higher price....
|
|
| 2025-09-04 | CASH |
|
Summary: Staying in cash as ABBV is in a clear uptrend but trading near resistance at $212.88 without a dip for entry, following recent exit on 8/29 at $210.4 to avoid chasing highs....
|
|
| 2025-09-03 | CASH |
|
Summary: Staying in cash as ABBV is in a confirmed uptrend but trading near resistance at $212.88 with no clear breakout, avoiding entry at the top of the range after recent exit on 8/29/2025 at $210.4....
|
|
| 2025-09-02 | CASH |
|
Summary: Staying in cash as ABBV is in an uptrend but trading near resistance at $212 with no clear dip for entry, following recent exit on 8/29/2025 at $210.4 amid overbought conditions and lack of new bullish catalysts....
|
|
| 2025-08-29 | SOLD |
|
Summary: Exiting long ABBV near $212 resistance after 13-bar hold from $198.64 entry, capturing gains in confirmed uptrend without reversal signals, supported by positive momentum and no imminent catalysts....
|
|
| 2025-08-28 | HOLD LONG |
|
Summary: Holding long in ABBV as the uptrend remains confirmed with price above both EMA and SMA, recent price action showing continued momentum toward $212 resistance without reversal signals, supported by positive sector trends and no imminent catalysts....
|
|
| 2025-08-27 | HOLD LONG |
|
Summary: Holding long in ABBV's confirmed uptrend with price above EMA and SMA, recent highs showing momentum, no reversal signals, and potential to test $212 resistance amid positive pharma sector tailwinds. Momentum indicators like MACD at 4.61 (positive and rising) and RSI at 66.43 (bullish but not overbought) support continuation, while Slow STO K/D at 86.16/91.46 indicates sustained buying pressure. Price is climbing toward the $212.88 resistance level noted in the chart, with historical patterns showing ABBV often extends rallies post-earnings or positive news, as seen in the July bounce from 186 to 198 before our entry....
|
|
| 2025-08-26 | HOLD LONG |
|
Summary: Holding long as ABBV remains in a confirmed uptrend with price above EMA and SMA, positive momentum from recent highs, no volume capitulation or imminent reversals, and approaching $212 resistance for potential multi-week extension....
|
|
| 2025-08-25 | HOLD LONG |
|
Summary: Holding long in confirmed uptrend with price above EMA/SMA, momentum building toward $212 resistance after recent consolidation, no imminent catalysts or reversals, and position requires extended hold....
|
|
| 2025-08-22 | HOLD LONG |
|
Summary: Holding long as uptrend persists with price above EMA/SMA, momentum toward $212 resistance intact, and position only 8 bars old requiring extended hold without reversal....
|
|
| 2025-08-21 | HOLD LONG |
|
Summary: Holding the long position as the stock remains in a confirmed uptrend with price above EMA and SMA, strong momentum continuing toward $212 resistance without reversal signals, and entry only 7 bars ago necessitating longer hold per strategy....
|
|
| 2025-08-20 | HOLD LONG |
|
Summary: Continuing to hold the long position in a confirmed uptrend with price above EMA and SMA, strong upward momentum pushing toward resistance at $212, no reversal signals yet, and entry only 6 bars ago requiring longer hold. Momentum indicators like MACD (4.5795 line above 3.4743 signal) and RSI (73.55, overbought but not extreme) support continued strength, as price has broken through prior highs and is approaching the noted resistance at $212.88. Visual indicators include a rising support trendline at $206.44 with recent bounces, aligning with the ongoing rally....
|
|
| 2025-08-19 | HOLD LONG |
|
Summary: Holding long in confirmed uptrend with price above EMA and SMA, strong momentum from recent rally, no reversal signals, and aiming for resistance near $212 while monitoring for pullbacks....
|
|
| 2025-08-18 | HOLD LONG |
|
Summary: Continuing to hold long position in strong uptrend with price above EMA and SMA, recent momentum pushing toward $212 resistance after positive earnings momentum, no reversal signals or immediate catalysts....
|
|
| 2025-08-15 | HOLD LONG |
|
Summary: Holding long in confirmed uptrend with price above EMA/SMA, building momentum toward $218 resistance after positive Q2 earnings beat and raised guidance, no immediate catalysts or reversal signals....
|
|
| 2025-08-14 | HOLD LONG |
|
Summary: Holding long in strong uptrend with price above EMA/SMA, continuing post-earnings momentum from July 31 beat, targeting $218 resistance amid positive pharma stability and no near-term catalysts....
|
|
| 2025-08-13 | HOLD LONG |
|
Summary: Holding long position in confirmed uptrend with price above EMA and SMA, building on post-earnings momentum from July 31 beat and raised guidance, targeting resistance near $218 with no immediate catalysts....
|
|
| 2025-08-12 | BUY |
|
Summary: Entering long in confirmed uptrend with price above EMA and SMA, following recent post-earnings strength and positive momentum near resistance, aiming for multi-week hold....
|
|
| 2025-08-11 | CASH |
|
Summary: Staying in cash as ABBV is near resistance at $198.98 in an uptrend but not on a clear dip, avoiding entry at the top of the range for a high-confidence multi-week long setup....
|
|
| 2025-08-08 | CASH |
|
Summary: Staying in cash as ABBV is in a clear uptrend post strong Q2 earnings beat and raised 2025 guidance, but current price near $198.98 resistance after recent rally suggests waiting for a dip to support like the rising trendline at ~$189 for a high-confidence long entry with favorable risk/reward....
|
|
| 2025-08-07 | SOLD |
|
Summary: Exiting long position near $198.98 resistance after post-earnings rally from $189.02 entry, locking in gains in confirmed uptrend with price above EMA/SMA, supported by strong Q2 results and raised 2025 guidance, no immediate reversal but opportunistic to take profits before potential pullback....
|
|
| 2025-08-06 | HOLD LONG |
|
Summary: Holding long position as uptrend continues with price above EMA/SMA, supported by strong Q2 earnings beat and raised guidance, no reversal signals despite approaching $198.98 resistance....
|
|
| 2025-08-05 | HOLD LONG |
|
Summary: Holding long in ongoing uptrend with price above EMA/SMA, positive momentum from Q2 earnings beat and raised guidance, nearing $198-200 resistance but no immediate catalysts or trend reversal signals....
|
|
| 2025-08-04 | HOLD LONG |
|
Summary: Continuing to hold long position post-Q2 earnings beat with raised guidance, as price remains in clear uptrend above EMA/SMA, recent highs at $196.42 signaling momentum toward $198-200 resistance over next weeks without immediate catalysts....
|
|
| 2025-08-01 | HOLD LONG |
|
Summary: Holding long position entered post strong Q2 earnings beat and raised guidance, with price in clear uptrend above EMA/SMA, recent breakout above $190 resistance on high volume signaling potential push to $198.98 level over next weeks....
|
|
| 2025-07-31 | BUY |
|
Summary: Entering long after positive Q2 earnings beat with strong Skyrizi/Rinvoq revenue and raised guidance, in clear uptrend with price above EMA/SMA, pulling back from intraday high near resistance for favorable entry....
|
|
| 2025-07-30 | CASH |
|
Summary: Staying in cash due to unclear trend with tightly bound EMA/SMA, frequent price crossings without capitulation, and impending earnings on July 31 that could introduce volatility despite positive analyst expectations....
|
|
| 2025-07-29 | CASH |
|
Summary: Staying in cash to avoid potential volatility from AbbVie's Q2 2025 earnings release on July 31, despite the current uptrend with EMA above SMA and price above both, positive analyst sentiment including buy ratings and a $250 target from recent reports, and strong fundamentals like immunology drug growth....
|
|
| 2025-07-28 | CASH |
|
Summary: Staying in cash to avoid potential volatility from the upcoming Q2 earnings on July 31, despite positive fundamental news on immunology drugs and an unclear but leaning uptrend with price near support....
|
|
| 2025-07-25 | SOLD |
|
Summary: Exiting long position ahead of July 31 earnings to avoid potential volatility from possible EPS miss, despite current uptrend and positive news on immunology drugs....
|
|
| 2025-07-24 | HOLD LONG |
|
Summary: Maintaining long position as uptrend persists with EMA above SMA, price above both, positive MACD crossover, and supportive fundamentals including strong Q1 earnings and upcoming Q2 results expected to show growth, despite earnings proximity....
|
|
| 2025-07-23 | HOLD LONG |
|
Summary: Holding long position in ABBV uptrend with price above EMA/SMA, positive fundamentals including Q1 earnings surge and analyst buy ratings targeting $250, despite upcoming Q2 earnings on July 31, 2025, as expectations remain strong for revenue and EPS growth....
|
|
| 2025-07-22 | HOLD LONG |
|
Summary: Holding long position as positive Q1 results, raised guidance, analyst buy ratings, and recent patent win support favorable Q2 earnings outcome on July 25 despite unclear trend, with price bouncing from support near entry for multi-week upside potential....
|
|
| 2025-07-18 | HOLD LONG |
|
Summary: Continuing the long position in ABBV as it holds above the rising support trendline with positive MACD crossover and neutral RSI, maintaining the multi-week hold setup from $186.39 amid stable pharma sector outlook....
|
|
| 2025-07-17 | HOLD LONG |
|
Summary: Holding long position in ABBV as it continues upward momentum from recent support bounce with positive MACD crossover and neutral RSI, supported by pharma sector stability and no major bearish catalysts....
|
|
| 2025-07-16 | HOLD LONG |
|
Summary: Holding the existing long position as ABBV continues upward momentum from the rising support trendline at $185 with positive MACD crossover, neutral RSI, and bullish catalysts like strong drug pipeline updates, for a multi-week hold targeting resistance near $194....
|
|
| 2025-07-15 | BUY |
|
Summary: Bounced off rising support trendline at $185.01 with positive MACD and neutral RSI, offering high-confidence long setup near support for multi-week hold amid pharma stability.
|
|